Benzodiazepines (BZ) are best known for their sedative and anxiolytic properties when given systemically. Not surprisingly, therefore, few clinicians would consider BZ as the first choice analgesic even though patients have reported that BZ can produce analgesia [5] . BZ are also administered intrathecally for analgesia and to relieve spasticity, but the complexity of this route precludes routine use. As the analgesic, sedative and anxiolytic effects of BZ are all mediated by GABA A receptors, there are questions as to whether these effects can be separated pharmacologically.
GABA A receptors are pentamers formed by the combination of at least 12 different subunits (6 alpha, 3 beta, 3 gamma, 1 delta, 1 epsilon, and 1 Pi) with the most common types consisting of two alpha, two beta and one gamma subunit. Each GABA A receptor subtype has a unique distribution in the CNS as well as specific pharmacological activity. BZ bind to, and modulate, the activity of a subgroup of GABA A receptors known, appropriately enough, as the BZ receptors. The binding site of BZ receptors is between an alpha subunit with a histidine residue (a1, 2, 3 or 5) and a gamma subunit. The subunit variation among the different BZ-binding receptors underlies the different clinical effects. For example, receptors with the a1 subunit mediate the sedative effects of BZ, while GABA A receptors with a2 or a3 subunits are responsible for the anxiolytic actions (Fig. 1) .
There is already evidence from preclinical studies that intrathecal injection of BZ is antinociceptive [1, 9] , and studies with ''anxioselective" agonists indicate that the analgesic effect is independent of the GABA A a1 subunit [8] . When administered systemically rather than intrathecally, however, analgesic effects can be masked or complicated by the sedative and anxiolytic manifestations, which have obviously reduced the use of BZ for pain. Now, Knabl and colleagues in this issue of Pain [7] present innovative data addressing the issue of analgesic versus other effects of BZ using several lines of mice with genetically altered GABA A receptors.
Knabl et al. used mice with point mutations of selected alpha subunits of the GABA A receptor and tested the effect of the deletions on formalin-induced pain behavior. First, they showed that in wild type mice systemically administered diazepam (the prototypical BZ) produced both analgesia and sedation, but in mice with point mutations of the a1 subunit the sedative effects were abolished, but the antinociception remained. Next, they showed that in mice with point mutations of the a1, together with a point mutation of the a2 or a3 subunits, both the sedative and the antinociceptive effects of systemically administered diazepam were abolished. Point mutations of the a1 together with a5 subunits did not abolish the antinociceptive effect of diazepam. These results suggest that the a2 and a3 subunits are responsible for the analgesic properties of the BZ. Finally, Knabl and colleagues showed that diazepam lost its antinociceptive effects in the a2 and a3 point mutation mice, whether the diazepam was administered systemically or intrathecally. Based on these results, the authors concluded that systemically administered diazepam works via spinal GABA A receptors.
These results are exciting because they provide the strongest evidence yet that analgesic and sedative effects of BZ are medi- 
